Lasa Supergenerics, a company in the Pharmaceuticals industry, reported revenue of ₹0.01 crore and a net loss of ₹1.84 crore for the September 2026 quarter.
Lasa Supergenerics (NSE: LASA-BE) closed at ₹4.01 on 16 Nov 2026. Its market capitalisation is ₹20 crore.
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.